TRKYY yields 6.77% · PFE yields 6.13%● Live data
📍 TRKYY pulled ahead of the other in Year 1
Combined, TRKYY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRKYY + PFE for your $10,000?
Türkiye Sinai Kalkinma Bankasi A.S. operates as a development and investment bank in Turkey and internationally. The company engages in the industrial investments, energy and resource efficiency, environmental investments, renewable energy, sustainable tourism, women's employment and equal opportunity, occupational health and safety, investments in developing regions, education and health investments, R&D and innovation, and working capital financing activities. It also provides project finance for energy generation and power plants; electricity distribution and natural gas distribution projects; mergers and acquisitions; logistics, transportation, and telecommunications; and public - private partnership projects. In addition, the company offers wholesale banking and SME financing, foreign trade finance, working capital financing, and machinery and equipment leasing services; letter of guarantees/external guarantees/letter of credits; and export/Eximbank endorsement, and country loans. Further, it provides corporate finance products and services, such as public offering preparation and brokerage, debt instrument issues, and mergers and acquisitions advisory; derivatives products, such as forwards, options, caps and floors, swaps, and swaptions; repo, warrant, and foreign derivative transactions; securities loans; brokerage for stock and bonds trading; and portfolio management and investment advisory services. Additionally, the company offers financial planning strategy, feasibility, valuation, and restructuring services, as well as sectoral analysis studies; and engineering and technical advisory, real estate appraisal, economic research, and sustainability consultancy services. Türkiye Sinai Kalkinma Bankasi A.S. was incorporated in 1950 and is headquartered in Istanbul, Turkey.
Full TRKYY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.